Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOLDOPAM MESYLATE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
In-hospital, short-term (up to 48 hours) management of severe hypertension (hypertensive crisis) when rapid, but quickly reversible, blood pressure reduction is required,Off-label: Management of hypertensive emergencies with acute renal impairment
Hypertension
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily hepatic via conjugation (glucuronidation and sulfation); CYP450 minimally involved.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 90% bound to plasma proteins, primarily albumin.
~90%, primarily to albumin
0.6–0.8 L/kg; moderate distribution consistent with limited tissue penetration.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Intravenous: 100%; no oral bioavailability due to extensive first-pass metabolism (not administered orally).
Oral: 50–60% (extensive first-pass metabolism)
No dose adjustment required for renal impairment; however, monitor for hypotension and electrolyte disturbances.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to increased risk of hypotension.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not FDA-approved for pediatric use; limited data: 0.2 mcg/kg/min IV infusion, titrated to effect; max 0.8 mcg/kg/min.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at low end of dosing range (0.1 mcg/kg/min) due to increased sensitivity to hypotension; monitor blood pressure closely.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
No FDA black box warning.
None
Hypotension risk: Monitor blood pressure closely; may cause excessive hypotension.,Tachycardia: Can increase heart rate; caution in patients with coronary ischemia or tachyarrhythmias.,Glaucoma risk: May increase intraocular pressure; avoid in patients with glaucoma.,Hypokalemia: Monitor potassium levels; may cause hypokalemia.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Known hypersensitivity to fenoldopam or any component,Patients with glaucoma
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
No specific food interactions reported. However, patients should avoid excessive caffeine or stimulants as they may affect blood pressure.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for fetal hypotension and decreased uteroplacental perfusion; use only if clearly needed. Avoid in severe preeclampsia or eclampsia due to risk of significant maternal hypotension.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
No data on presence in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risk of infant exposure.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No standard dose adjustments required; but use lowest effective dose due to increased sensitivity to hypotensive effects in pregnancy. Titrate carefully.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Fenoldopam is a dopamine D1-like receptor agonist used for severe hypertension and hypertensive emergencies. It causes rapid, titratable blood pressure reduction without the toxic metabolites seen with nitroprusside. It also increases renal blood flow and natriuresis, making it beneficial in patients with renal impairment. Avoid in patients with glaucoma (increases intraocular pressure) or sulfite allergy (contains sodium metabisulfite).
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
This medication is given intravenously and is only used in a hospital setting.,You will have your blood pressure and heart rate monitored continuously during the infusion.,Report any headache, flushing, or dizziness to your nurse.,Do not stop the infusion suddenly; the dose will be gradually decreased.,Avoid consuming caffeine or other stimulants during treatment.,Tell your healthcare provider if you have glaucoma or a history of sulfite allergy.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
"Fenoldopam, a dopamine D1-like receptor agonist used for in-hospital blood pressure reduction, can potentiate the hypotensive and hypovolemic effects of the loop diuretic ethacrynic acid. Ethacrynic acid induces sodium and water diuresis, leading to reduced intravascular volume; Fenoldopam causes arterial vasodilation. When co-administered, the combined hemodynamic stress may increase the risk of excessive hypotension, renal hypoperfusion, and acute kidney injury, particularly in patients with compromised cardiac output or volume depletion."
"Iloprost, a prostacyclin analog, enhances vasodilation and inhibits platelet aggregation via IP receptor activation, increasing intracellular cAMP. Fenoldopam, a selective dopamine D1 receptor agonist, induces systemic and renal vasodilation through cAMP-dependent pathways. Concomitant use amplifies the hypotensive effect, potentially leading to severe hypotension, reflex tachycardia, and end-organ hypoperfusion, especially in patients with compromised cardiovascular reserve."
"Amlodipine, a dihydropyridine calcium channel blocker, reduces peripheral vascular resistance by inhibiting calcium influx into vascular smooth muscle cells. Fenoldopam, a selective dopamine D1 receptor agonist, causes arterial vasodilation, particularly in the renal and mesenteric beds. The concurrent use of these two vasodilatory agents leads to additive hypotension, potentially causing symptomatic drops in blood pressure, dizziness, and syncope, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOLDOPAM MESYLATE vs ALDORIL 15, answered by our medical review team.
FENOLDOPAM MESYLATE is a Antihypertensive that works by Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOLDOPAM MESYLATE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOLDOPAM MESYLATE is: 0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOLDOPAM MESYLATE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOLDOPAM MESYLATE is classified as Category C. Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for feta. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.